• Sean Maduck, President, Corcept Endocrinology, reported June 1 transactions in Corcept Therapeutics common stock.
• Exercised stock options for 25,000 shares at USD 8.27.
• Sold 25,000 shares at weighted-average prices of USD 70.11 and USD 70.75.
• Acquired 1,230 shares at USD 70.44 and received 615 restricted shares.
• Withheld 452 shares at USD 70.44 for tax obligations; direct holdings ended at 9,755 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-256013), on June 03, 2026, and is solely responsible for the information contained therein.